Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Connick

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Neurology|May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging studyIan Marshall, Michael J Thrippleton, Mark E Bastin, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
BMJ Open|June 29, 2022
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosisPatrick K A Kearns, Sarah J Martin, Jessie Chang, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
BMJ Open|February 1, 2023
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensusCharis Wong, Jenna M Gregory, Jing Liao, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Neurology|May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging studyIan Marshall, Michael J Thrippleton, Mark E Bastin, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
BMJ Open|June 29, 2022
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosisPatrick K A Kearns, Sarah J Martin, Jessie Chang, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
BMJ Open|February 1, 2023
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensusCharis Wong, Jenna M Gregory, Jing Liao, et al.
Pageof 4